Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Proof of concept
- Acronyms RECEDE-CHF
- 16 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 31 Dec 2018.
- 19 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated